Advances in Therapeutic Melanoma Vaccines (2010–2025)
Vaccines · 07.08.2026 · 14 (8) · 682
DOI: 10.3390/vaccines14080682 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 07.08.2026. Verfasst von Michael Y Bian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. Die Arbeit nennt 205 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Immune checkpoint inhibitors (ICIs) and other systemic therapies can extend the survival of many patients with advanced melanoma, renewing interest in complementary strategies for unresectable or metastatic disease. Therapeutic cancer vaccines represent a possible approach. Recent evidence suggests commercially available mRNA vaccines can sensitize tumors to ICIs, challenging prior assumptions about neoantigen presentation. Despite renewed public interest in personalized cancer vaccine development, the proliferation of narrative and scoping reviews has not been matched by systematic mechanistic synthesis—platforms investigated across the 2010s and 2020s have not been rigorously compared within a single article. Accordingly, this review focuses on major vaccine platforms and proposes a comparative framework for understanding therapeutic melanoma vaccine development and immunologic rationale.
Methods
Melanoma vaccine clinical trials listed on ClinicalTrials.gov were identified from 2010 to 2025. Eligible studies were screened and included in a qualitative review evaluating trial characteristics, vaccine platforms, study design, and reported outcomes.
Results
There is one active Phase III clinical trial for melanoma vaccines in the US. Key principles of melanoma vaccinology include adjuvant, antigen, and delivery platform selection. From 2010 to 2025, four vaccine candidates advanced to Phase III trials, two provided Phase III results for peer review, one trial is ongoing, and no vaccines have been FDA-approved. Inconsistent reporting of outcomes and a lack of published results limited comparability across studies, precluding formal meta-analysis.
Conclusions
Therapeutic melanoma vaccine options remain limited by translational challenges in study design and reporting gaps. This review synthesizes contemporary clinical trial activity and immunologic principles to inform future research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
- Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
- Case Comprehensive Cancer Center, Cleveland, OH 44106, USA.
- Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH 44106, USA.
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
ORCID-Profile: Michael Y Bian, Ankit Mangla, Devarati Mitra, Luke D Rothermel
Zitieren
APA
Bian, M. Y., Stevens, R., Mangla, A., Mitra, D., Zaorsky, N. G., Bordeaux, J. S., & Rothermel, L. D. (2026). Advances in Therapeutic Melanoma Vaccines (2010–2025). Vaccines, 14(8), 682. https://doi.org/10.3390/vaccines14080682
Vancouver
Bian MY, Stevens R, Mangla A, Mitra D, Zaorsky NG, Bordeaux JS, et al. Advances in Therapeutic Melanoma Vaccines (2010–2025). Vaccines. 2026;14(8):682. doi:10.3390/vaccines14080682
BibTeX
@article{Bian2026,
author = {Bian, Michael Y and Stevens, Reagan and Mangla, Ankit and Mitra, Devarati and Zaorsky, Nicholas G and Bordeaux, Jeremy S and Rothermel, Luke D},
title = {Advances in Therapeutic Melanoma Vaccines (2010–2025)},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {8},
pages = {682},
doi = {10.3390/vaccines14080682}
}
EUVIMED